Literature DB >> 9667796

Multiresistant bacteria as a hospital epidemic problem.

P J Dennesen1, M J Bonten, R A Weinstein.   

Abstract

Since the introduction of antibiotics into clinical use, bacteria have protected themselves by developing antibiotic resistance mechanisms. Currently, there are increasing problems worldwide with multiresistant bacteria. These problems are especially evident within hospitals, where they frequently present as nosocomial epidemics. Currently, the most important nosocomial resistance problems on a global scale are caused by methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and Enterobacteriaceae with plasmid-encoded extended-spectrum beta-lactamases. In this review we describe the characteristics of nosocomial epidemics of these three groups of multiresistant nosocomial pathogens. Despite the differences in bacterial species, the differences in mechanisms of resistance, the different ecological niches and the different infections caused by these pathogens, there are striking similarities in the variables determining nosocomial spread. The existence of each of these multiresistant micro-organisms and their concurrent spread seem to result from extensive antibiotic use and lapses in compliance with infection control measures. Problems with these bacteria became evident as monoclonal outbreaks, soon followed by establishment of endemicity especially in intensive care units. Finally, endemicity seems to be established on general hospital wards and in chronic care facilities and nursing homes, creating a continuous influx of colonized patients into special care wards. High compliance with infection control measures and a prudent and more restrictive use of antibiotics are the key measures to prevent these epidemics.

Entities:  

Mesh:

Year:  1998        PMID: 9667796     DOI: 10.3109/07853899808999401

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  14 in total

1.  Antimicrobial resistance problems in a university hospital.

Authors:  Uchenna Chinedu Ozumba
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

2.  Circumventing the effect of product toxicity: development of a novel two-stage production process for the lantibiotic gallidermin.

Authors:  G Valsesia; G Medaglia; M Held; W Minas; S Panke
Journal:  Appl Environ Microbiol       Date:  2006-12-28       Impact factor: 4.792

3.  Incidence and characterization of integrons, genetic elements mediating multiple-drug resistance, in avian Escherichia coli.

Authors:  L Bass; C A Liebert; M D Lee; A O Summers; D G White; S G Thayer; J J Maurer
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Macrolide resistance genes in Enterococcus spp.

Authors:  A Portillo; F Ruiz-Larrea; M Zarazaga; A Alonso; J L Martinez; C Torres
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  Plasmid-encoded MucB protein is a DNA polymerase (pol RI) specialized for lesion bypass in the presence of MucA', RecA, and SSB.

Authors:  M Goldsmith; L Sarov-Blat; Z Livneh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

6.  A soxRS-constitutive mutation contributing to antibiotic resistance in a clinical isolate of Salmonella enterica (Serovar typhimurium).

Authors:  A Koutsolioutsou; E A Martins; D G White; S B Levy; B Demple
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Constitutive soxR mutations contribute to multiple-antibiotic resistance in clinical Escherichia coli isolates.

Authors:  Anastasia Koutsolioutsou; Samuel Peña-Llopis; Bruce Demple
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  In vitro antimicrobial activity of GSQ1530, a new heteroaromatic polycyclic compound.

Authors:  Yigong Ge; Stacey Difuntorum; Sofia Touami; Ian Critchley; Roland Bürli; Vernon Jiang; Ken Drazan; Heinz Moser
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.

Authors:  David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Thomas Nichols; Peter Stephens; Alan P Johnson; Robert C George
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

10.  Pharmacology of novel heteroaromatic polycycle antibacterials.

Authors:  M Gross; R Bürli; P Jones; M Garcia; B Batiste; J Kaizerman; H Moser; V Jiang; U Hoch; J-X Duan; R Tanaka; K W Johnson
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.